Clinical Trials Logo

Metabolic Syndrome X clinical trials

View clinical trials related to Metabolic Syndrome X.

Filter by:

NCT ID: NCT01106118 Completed - Clinical trials for Erectile Dysfunction

Therapeutic Effectiveness of Vardenafil in Patients With Erectile Dysfunction and Metabolic Syndrome in Daily Clinical Practice

REVITALISE
Start date: January 2010
Phase: N/A
Study type: Observational

The primary goal of this international non-interventional study is to investigate the therapeutic effectiveness of vardenafil (film-coated tablet) in Erectile Dysfunction patients with the Metabolic Syndrome in daily clinical practice. It will include a large number of patients with various underlying conditions with different cultural and demographic backgrounds from different geographic areas.

NCT ID: NCT01103921 Completed - Metabolic Syndrome Clinical Trials

The Metabolic Effects of Consuming Sugar-Sweetened Beverages for Two Weeks

DRS
Start date: October 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the effects of consumption of sugar-sweetened beverages on blood triglycerides and cholesterol, cholesterol concentrations, and the body's sensitivity to insulin.

NCT ID: NCT01103245 Completed - Diabetes Mellitus Clinical Trials

Aldosterone and the Metabolic Syndrome

Start date: March 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the effects of mineralocorticoid receptor (MR) antagonism and renin inhibition on glucose metabolism in humans.

NCT ID: NCT01099306 Completed - Metabolic Syndrome Clinical Trials

Pharmacist - Physician Collaborative Approach to the Management of Metabolic Syndrome

Start date: March 2009
Phase: N/A
Study type: Interventional

This study devised an experimental focused pharmaceutical care program, allowed a clinical pharmacist to work in a physician office to assess and manage patients' metabolic syndrome status and its individual components. This study described the clinical benefits of physician- clinical pharmacist interaction in achieving improved glycemic control, lipid and blood pressure measurements, involving medication, diet, physical activity and patient heath care counseling.

NCT ID: NCT01094158 Completed - Metabolic Syndrome Clinical Trials

Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis

Aramchol003
Start date: November 2010
Phase: Phase 2
Study type: Interventional

Primary purpose: Compare the changes in liver triglycerides concentration in the Aramchol versus the placebo arm following three month treatment. Secondary purpose: Comparing liver enzymes, markers of endothelial dysfunction, insulin resistance, SCD1 activity and cholesterol synthesis and lipid levels, between the Aramchol and the placebo arms.

NCT ID: NCT01087632 Completed - Metabolic Syndrome Clinical Trials

Armolipid Plus and Metabolic Syndrome

Start date: September 2009
Phase: N/A
Study type: Interventional

Metabolic syndrome is a highly prevalent condition characterized by visceral obesity, abnormalities of glucidic and lipid metabolism, and increased risk for cardiovascular events. Such findings appear to be associated with a decrease in insulin sensitivity. Management of metabolic syndrome is currently aimed at treating individual components of the disease without addressing this underlying pathophysiologic mechanism; this translates into multidrug regimens, high costs and patient compliance issues. Armolipid Plus (an association of berberine 500 mg, red yeast rice titled in 3 mg monacolin K,policosanol 10 mg,coenzyme Q10 2 mg,astaxanthin 0,5 mg,folic acid 0,2 mg) has been found to be effective at reducing blood cholesterol and triglycerides, and at improving endothelial function; subgroup analyses also suggested a benefit on indices of insulin resistance. Aim of the study is to evaluate the effects of Armolipid Plus on insulin sensitivity and on the diagnostic parameters of metabolic syndrome. 60 patients will be enrolled in this randomized, double-blind, placebo-controlled trial; active treatment will consist of Armolipid Plus (1 tbl qd). Primary end point will be the reduction of the insulin/glucose ratio, both after overnight fast (HOMA index) and after an oral glucose tolerance test (OGTT).

NCT ID: NCT01087086 Completed - Obesity Clinical Trials

Reduction of the Metabolic Syndrome in Navarra-Spain

RESMENA-S
Start date: January 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether a dietary pattern based on crononutrition and dietary training, together with dietary and psychological control, can reduce the body weight, improve the oxidative and inflammatory state in subjects with diagnosed metabolic syndrome features and can reduce the prevalence of the Metabolic syndrome in the population.

NCT ID: NCT01086137 Completed - Hypertension Clinical Trials

Biomarkers of Metabolic Syndrome and Prediabetes

Start date: March 2010
Phase: N/A
Study type: Observational

The purpose of this study is to investigate the feasibility of using salivary biomarkers to screen for complications of metabolic syndrome including prediabetes.

NCT ID: NCT01080989 Completed - Hypertension Clinical Trials

The Sero-Prevalence and Genetic Study for the Infectious Diseases and Metabolic Syndrome in Solomon Islands

Start date: March 2009
Phase: N/A
Study type: Interventional

The study project can be divided into two parts: (1) health screening for the community and (2) clinical diagnosis and treatment for patients at National Referral Hospital (NRH) in Solomon islands. The health screening includes a questionnaire, stool parasitic screening and blood laboratory tests. A total of 800 subjects will participate in this study. The collected samples are venous blood (20 ml/per subject) and stool in order to conduct the related tests mentioned above. As for the collection of target patients, KMUH will cooperate with NRH to collect two kinds of blood samples: the blood samples of confirmed malarial cases and those of cases suspicious of Flaviviral, Alpha-viral, Rickettsial, and Leptospiral infections. The expected received cases are 600 each year. The venous blood samples (20 ml/per subject) will be used to conduct related tests mentioned above. At the same time, the subjects will also have to fill out a related questionnaire which includes height, weight, waist line, heath behavior and habit, and past history, etc.

NCT ID: NCT01077479 Completed - Metabolic Syndrome Clinical Trials

Metformin in Preventing Androgen Deprivation Therapy Induced Insulin Resistance and Metabolic Syndrome

MVENT
Start date: February 2010
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to assess the efficacy of metformin in abrogating androgen deprivation therapy (ADT) induced insulin resistance as measured by homeostasis model assessment (HOMAIR) in men with non-metastatic prostate cancer.